Abstract: The invention provides an A? peptide aggregation inhibitor, an A? peptide toxicity reducing agent, and a preventive and/or therapeutic agent for Alzheimer's disease. The oxidized A? peptide in which one or more amino acid residues of A? peptide have been oxidized (excluding an oxidized A? peptide in which only Met has been oxidized).

Abstract: Provided is a compound which is bioapplicable and amyloid-selective, and is useful as an amyloid oxygenation catalyst applicable not only to A? peptides but also to other amyloids, and a preventive/therapeutic drug for an amyloid-related disease using the same.

Abstract: Provided is a compound which is bioapplicable and amyloid-selective, and is useful as an amyloid oxygenation catalyst applicable not only to A? peptides but also to other amyloids, and a preventive/therapeutic drug for an amyloid-related disease using the same.

Abstract: Provided is a compound which is bioapplicable and amyloid-selective, and is useful as an amyloid oxygenation catalyst applicable not only to A? peptides but also to other amyloids, and a preventive/therapeutic drug for an amyloid-related disease using the same.

Abstract: Provided is a compound which is bioapplicable and amyloid-selective, and is useful as an amyloid oxygenation catalyst applicable not only to A? peptides but also to other amyloids, and a preventive/therapeutic drug for an amyloid-related disease using the same.

Abstract: Provided is a compound which is useful as an in vivo applicable, amyloid-oxygenating catalyst selective for amyloid and applicable not only to an A? peptide, but also to other amyloids and a drug containing the compound for preventing and/or treating amyloid-related diseases.

Abstract: The invention provides an A? peptide aggregation inhibitor, an A? peptide toxicity reducing agent, and a preventive and/or therapeutic agent for Alzheimer's disease. The oxidized A? peptide in which one or more amino acid residues of A? peptide have been oxidized (excluding an oxidized A? peptide in which only Met has been oxidized).

Abstract: The invention provides an A? peptide aggregation inhibitor, an A? peptide toxicity reducing agent, and a preventive and/or therapeutic agent for Alzheimer's disease. The oxidized A? peptide in which one or more amino acid residues of A? peptide have been oxidized (excluding an oxidized A? peptide in which only Met has been oxidized).

Abstract: It is intended to provide: a compound useful as an amyloid oxidation catalyst which is applicable in vivo and is applicable not only to A? peptides but to other amyloids; and a prophylactic or therapeutic drug for an amyloid-related disease, comprising the same. The present invention provides a benzothiazole compound represented by the following formula (1) wherein X represents a halogen atom; R1 represents an optionally substituted hydrocarbon group; R2 represents a hydrogen atom or an optionally substituted hydrocarbon group; R3 and R4 are the same or different and each represent a hydrogen atom, an optionally substituted hydrocarbon group, an alkoxy group, a halogen atom, an amino group, a nitro group, or a cyano group; R2 and R4 optionally together form an alkylene group; and R5 represents an anion.

Abstract: Provided are a compound which is useful as an in vivo applicable, amyloid-oxygenating catalyst selective for amyloid and applicable not only to an A? peptide but also to other amyloids and a drug containing the compound for preventing and/or treating amyloid-related-diseases.

Abstract: Provided is a novel compound which has an excellent A? aggregation inhibitory effect and is useful as a pharmaceutical. An amide compound represented by the formula (1) or a salt thereof, wherein Z represents CH or N; A and B are the same or different and each represents —CH2—, —O—, —S—, or —NH—; R1 and R2 are the same or different and each represents a branched alkyl group, a branched alkenyl group, an optionally substituted aromatic hydrocarbon group, an optionally substituted aralkyl group, an optionally substituted cycloalkyl group, or an optionally substituted aromatic heterocyclic group; and R3 represents a branched alkyl group, a branched alkenyl group, an optionally substituted cycloalkyl group, or an optionally substituted aralkyl group.

Abstract: A cyclic peptide or a salt thereof of formula (1): X-Leu-Val-Y1-Y2 (1), where X is Lys, Arg, His, Ala, Gly, Ser, or Thr; and Y1 and Y2, which are identical to or different from each other, each represent a group represented by formula (2): where Ar1 represents an aromatic hydrocarbon group or an aromatic heterocyclic group; R1 represents a hydrogen atom, an alkyl group, a cycloalkyl group, a haloalkyl group, an aromatic hydrocarbon group, or an aromatic heterocyclic group; and n is an integer from 0 to 2. In the cyclic peptide has an ?-amino group at the amino terminus of the amino acid sequence which is linked, via a peptide bond, to the carboxyl group at the carboxyl terminus of the amino acid sequence.

Abstract: It is intended to provide: a compound useful as an amyloid oxidation catalyst which is applicable in vivo and is applicable not only to A? peptides but to other amyloids; and a prophylactic or therapeutic drug for an amyloid-related disease, comprising the same. The present invention provides a benzothiazole compound represented by the following formula (1) wherein X represents a halogen atom; R1 represents an optionally substituted hydrocarbon group; R2 represents a hydrogen atom or an optionally substituted hydrocarbon group; R3 and R4 are the same or different and each represent a hydrogen atom, an optionally substituted hydrocarbon group, an alkoxy group, a halogen atom, an amino group, a nitro group, or a cyano group; R2 and R4 optionally together form an alkylene group; and R5 represents an anion.

Abstract: Provided is a novel compound which has an excellent A? aggregation inhibitory effect and is useful as a pharmaceutical. An amide compound represented by the formula (1) or a salt thereof, wherein Z represents CH or N; A and B are the same or different and each represents —CH2—, —O—, —S—, or —NH—; R1 and R2 are the same or different and each represents a branched alkyl group, a branched alkenyl group, an optionally substituted aromatic hydrocarbon group, an optionally substituted aralkyl group, an optionally substituted cycloalkyl group, or an optionally substituted aromatic heterocyclic group; and R3 represents a branched alkyl group, a branched alkenyl group, an optionally substituted cycloalkyl group, or an optionally substituted aralkyl group.

Abstract: The invention provides an A? peptide aggregation inhibitor, an A? peptide toxicity reducing agent, and a preventive and/or therapeutic agent for Alzheimer's disease. The oxidized A? peptide in which one or more amino acid residues of A? peptide have been oxidized (excluding an oxidized A? peptide in which only Met has been oxidized).

Abstract: Provided is a novel compound which has excellent inhibitory activity for A? aggregation, and which is useful as a drug.

Abstract: Compositions and methods related to ester insulin or derivatives thereof are provided. The compositions include GluA4-ThrB30 ester insulin, in which side chains of GluA4 and ThrB30 of native human insulin or an insulin analogue such as insulin lispro are covalently linked via a single ester bond. The ester insulin is efficiently folded, forming the desired disulfides. The ThrB30-GluA4 ester bond can be cleaved in vitro or in vivo to give the desired folded insulin with full biological activity. The ester insulin is readily prepared by total chemical synthesis, and amendable to cost-effective, large scale manufacturing. Also provided are pharmaceutical compositions and kits for use in practicing the subject methods. Also provided are methods of using the subject compositions and kits in the treatment of a variety of different disease conditions, particularly glucose metabolic disorders such as diabetes and obesity.